Not only is COVID-19 proliferating human suffering in terms of its health implications, but it has also had a major impact on global economies. Researchers all over the world are working relentlessly for the development of treatments and vaccines for COVID-19.

Critically ill patients with COVID-19 have reported respiratory failure, acute respiratory distress syndrome (ARDS), sepsis and septic shock, thromboembolism and/or multiorgan failure, including Acute Kidney Injury and cardiac injury. As more data have become available, we are increasingly learning of the vascular manifestations of COVID-19. Notably, coagulopathy, in the form of both venous and arterial thromboembolism, has been reported in severe COVID-19 cases.

In the context of the health crisis caused by COVID-19, the WHO has published Clinical Management Guidelines for patients critically ill from the coronavirus infection. An important recommendation in these guidelines is the use of low molecular weight heparin (such as enoxaparin) for pharmacological prophylaxis in hospitalized COVID-19 patients to prevent untoward coagulative events like venous thromboembolism, stroke, deep venous thrombosis, pulmonary embolism and acute coronary syndrome.

Enoxaparin, an essential medicine by the World Health Organization, is among the most commonly used anticoagulant for the prevention and treatment of thrombosis worldwide. Various research papers also recommended the use of enoxaparin to alleviate the coagulopathy-related risks of COVID-19. It is also important to mention that enoxaparin is used as a complementary therapy in the treatment of secondary complications associated with COVID 19. It is not a primary or preventive solution for COVID-19 patients.

As a major manufacturer and supplier of Enoxaparin (see Products), we at Venus Remedies Limited (VRL) are closely monitoring the evolving COVID-19 situation and taking measures in line with the WHO and Indian Health authorities to mitigate the effects of this situation. At the same time, as a responsible pharmaceutical company, we are committed to ensuring the continuous production and distribution of Enoxaparin and all other essential medicines with the highest quality and safety standards to tackle this global pandemic.